Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Robinson PC, Maksymowych WP, Gensler L, Rudwaleit M, Hoepken B, Bauer L, Kumke T, Kim M, Deodhar A (2022)
In: ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA. American College of Rheumatology (Ed); Arthritis & Rheumatology, 74(Suppl. 9). Hoboken: Wiley: 808-810.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Robinson, Philip C.;
Maksymowych, Walter P.;
Gensler, Lianne;
Rudwaleit, MartinUniBi;
Hoepken, Bengt;
Bauer, Lars;
Kumke, Thomas;
Kim, Mindy;
Deodhar, Atul
herausgebende Körperschaft
American College of Rheumatology
Einrichtung
Erscheinungsjahr
2022
Titel des Konferenzbandes
ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA
Serien- oder Zeitschriftentitel
Arthritis & Rheumatology
Band
74
Ausgabe
Suppl. 9
Seite(n)
808-810
ISSN
2326-5191
eISSN
2326-5205
Page URI
https://pub.uni-bielefeld.de/record/2968214
Zitieren
Robinson PC, Maksymowych WP, Gensler L, et al. Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status. In: American College of Rheumatology, ed. ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA. Arthritis & Rheumatology. Vol 74. Hoboken: Wiley; 2022: 808-810.
Robinson, P. C., Maksymowych, W. P., Gensler, L., Rudwaleit, M., Hoepken, B., Bauer, L., Kumke, T., et al. (2022). Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status. In American College of Rheumatology (Ed.), Arthritis & Rheumatology: Vol. 74. ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA (pp. 808-810). Hoboken: Wiley. https://doi.org/10.1002/art.42355
Robinson, Philip C., Maksymowych, Walter P., Gensler, Lianne, Rudwaleit, Martin, Hoepken, Bengt, Bauer, Lars, Kumke, Thomas, Kim, Mindy, and Deodhar, Atul. 2022. “Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status”. In ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, ed. American College of Rheumatology, 74:808-810. Arthritis & Rheumatology. Hoboken: Wiley.
Robinson, P. C., Maksymowych, W. P., Gensler, L., Rudwaleit, M., Hoepken, B., Bauer, L., Kumke, T., Kim, M., and Deodhar, A. (2022). “Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status” in ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology ed. Arthritis & Rheumatology, vol. 74, (Hoboken: Wiley), 808-810.
Robinson, P.C., et al., 2022. Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status. In American College of Rheumatology, ed. ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA. Arthritis & Rheumatology. no.74 Hoboken: Wiley, pp. 808-810.
P.C. Robinson, et al., “Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status”, ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, American College of Rheumatology, ed., Arthritis & Rheumatology, vol. 74, Hoboken: Wiley, 2022, pp.808-810.
Robinson, P.C., Maksymowych, W.P., Gensler, L., Rudwaleit, M., Hoepken, B., Bauer, L., Kumke, T., Kim, M., Deodhar, A.: Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status. In: American College of Rheumatology (ed.) ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA. Arthritis & Rheumatology. 74, p. 808-810. Wiley, Hoboken (2022).
Robinson, Philip C., Maksymowych, Walter P., Gensler, Lianne, Rudwaleit, Martin, Hoepken, Bengt, Bauer, Lars, Kumke, Thomas, Kim, Mindy, and Deodhar, Atul. “Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status”. ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA. Ed. American College of Rheumatology. Hoboken: Wiley, 2022.Vol. 74. Arthritis & Rheumatology. 808-810.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar